|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNX11 |
Gene summary for SNX11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNX11 | Gene ID | 29916 |
| Gene name | sorting nexin 11 | |
| Gene Alias | SNX11 | |
| Cytomap | 17q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9Y5W9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29916 | SNX11 | LZE24T | Human | Esophagus | ESCC | 1.07e-11 | 1.65e-01 | 0.0596 |
| 29916 | SNX11 | P1T-E | Human | Esophagus | ESCC | 6.02e-04 | 2.19e-01 | 0.0875 |
| 29916 | SNX11 | P2T-E | Human | Esophagus | ESCC | 3.00e-20 | 1.64e-01 | 0.1177 |
| 29916 | SNX11 | P4T-E | Human | Esophagus | ESCC | 5.76e-12 | 2.63e-01 | 0.1323 |
| 29916 | SNX11 | P5T-E | Human | Esophagus | ESCC | 3.08e-09 | 7.96e-02 | 0.1327 |
| 29916 | SNX11 | P8T-E | Human | Esophagus | ESCC | 4.56e-12 | 1.10e-01 | 0.0889 |
| 29916 | SNX11 | P9T-E | Human | Esophagus | ESCC | 1.04e-04 | 6.05e-02 | 0.1131 |
| 29916 | SNX11 | P10T-E | Human | Esophagus | ESCC | 3.04e-21 | 1.88e-01 | 0.116 |
| 29916 | SNX11 | P11T-E | Human | Esophagus | ESCC | 1.73e-07 | 1.82e-01 | 0.1426 |
| 29916 | SNX11 | P12T-E | Human | Esophagus | ESCC | 3.56e-23 | 2.17e-01 | 0.1122 |
| 29916 | SNX11 | P15T-E | Human | Esophagus | ESCC | 8.76e-09 | 1.63e-01 | 0.1149 |
| 29916 | SNX11 | P16T-E | Human | Esophagus | ESCC | 7.34e-20 | 2.36e-01 | 0.1153 |
| 29916 | SNX11 | P17T-E | Human | Esophagus | ESCC | 2.73e-03 | 1.82e-01 | 0.1278 |
| 29916 | SNX11 | P20T-E | Human | Esophagus | ESCC | 5.36e-08 | 1.86e-01 | 0.1124 |
| 29916 | SNX11 | P21T-E | Human | Esophagus | ESCC | 4.33e-13 | 2.27e-01 | 0.1617 |
| 29916 | SNX11 | P22T-E | Human | Esophagus | ESCC | 7.44e-09 | 1.49e-01 | 0.1236 |
| 29916 | SNX11 | P23T-E | Human | Esophagus | ESCC | 3.09e-10 | 2.09e-01 | 0.108 |
| 29916 | SNX11 | P24T-E | Human | Esophagus | ESCC | 1.66e-14 | 1.92e-01 | 0.1287 |
| 29916 | SNX11 | P26T-E | Human | Esophagus | ESCC | 3.25e-22 | 2.48e-01 | 0.1276 |
| 29916 | SNX11 | P27T-E | Human | Esophagus | ESCC | 8.40e-19 | 2.22e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605014 | Esophagus | ESCC | vesicle organization | 211/8552 | 300/18723 | 2.85e-18 | 2.87e-16 | 211 |
| GO:00160508 | Oral cavity | OSCC | vesicle organization | 189/7305 | 300/18723 | 2.40e-17 | 2.14e-15 | 189 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNX11 | SNV | Missense_Mutation | novel | c.200N>C | p.Arg67Thr | p.R67T | Q9Y5W9 | protein_coding | deleterious(0) | possibly_damaging(0.903) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| SNX11 | SNV | Missense_Mutation | rs759226849 | c.172N>T | p.Arg58Cys | p.R58C | Q9Y5W9 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SNX11 | SNV | Missense_Mutation | c.360N>G | p.Ser120Arg | p.S120R | Q9Y5W9 | protein_coding | tolerated(0.1) | probably_damaging(0.999) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| SNX11 | SNV | Missense_Mutation | novel | c.416N>C | p.Val139Ala | p.V139A | Q9Y5W9 | protein_coding | tolerated(0.18) | probably_damaging(0.984) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SNX11 | SNV | Missense_Mutation | rs371948730 | c.613G>C | p.Glu205Gln | p.E205Q | Q9Y5W9 | protein_coding | tolerated_low_confidence(0.05) | benign(0.04) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SNX11 | SNV | Missense_Mutation | c.178N>C | p.Tyr60His | p.Y60H | Q9Y5W9 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SNX11 | SNV | Missense_Mutation | c.383N>A | p.Ser128Asn | p.S128N | Q9Y5W9 | protein_coding | deleterious(0.01) | possibly_damaging(0.903) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SNX11 | SNV | Missense_Mutation | rs775844175 | c.169C>T | p.Arg57Trp | p.R57W | Q9Y5W9 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
| SNX11 | SNV | Missense_Mutation | novel | c.642N>T | p.Glu214Asp | p.E214D | Q9Y5W9 | protein_coding | tolerated_low_confidence(0.08) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| SNX11 | SNV | Missense_Mutation | rs376480018 | c.299N>A | p.Arg100Gln | p.R100Q | Q9Y5W9 | protein_coding | tolerated(0.1) | probably_damaging(0.998) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |